Skip to main content

149 Abilify Plaintiffs' Claims Dismissed

149 Abilify Plaintiffs' Claims Dismissed

149 Abilify Plaintiffs' Claims Dismissed

Introduction

On Tuesday, U.S. District Judge M. Casey Rodgers dismissed 149 cases linked to the side effects of the antipsychotic drug Abilify due to plaintiffs' failure to comply with court orders following the announcement of a global settlement by the defendants Otsuka Pharmaceutical Co. Ltd. and Bristol-Myers Squibb Co. in February.

Judge Rodgers discovered that the dismissed plaintiffs didn't follow the directions by either failing to submit supporting documentation for their claims or submitting documentation that failed to establish that they used Abilify.

A separate order published on September 9 by Judge Rodgers indicates that four plaintiffs submitted satisfactory responses and would face no sanctions. The Plaintiffs were found eligible for a settlement award as they submitted all the necessary documentation post the initial and follow-up notice in April from the claims administrator. Three of them accepted a settlement award on August 9, and one plaintiff accepted the award on September 11. These four are in the process of submitting their releases.

There are more than 600 lawsuits originally filed in 2016 by consumers from several states, including Arizona, California, Delaware, Florida, New Jersey, New York, and Pennsylvania against Abilify manufacturers. The multidistrict litigation MDL No. 2734 (In Re: Abilify Compulsive Behavior Products Liability Litigation) was formed in October 2016 in the Northern District of Florida for coordinated discovery and pre-trial proceedings.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!